<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810862</url>
  </required_header>
  <id_info>
    <org_study_id>pimecrolimus1</org_study_id>
    <nct_id>NCT00810862</nct_id>
  </id_info>
  <brief_title>Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children</brief_title>
  <official_title>A 3-Week, Single-Blind, Placebo-Controlled, Within-Patient, Randomized Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primecrolimus cream 1% is effective in the treatment of atopic dermatitis in African American
      children.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of subject enrollment over the past two years.
  </why_stopped>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in modified Modified EASI score a dermatologic evaluation of response to topical therapy for atopic dermatitis</measure>
    <time_frame>at baseline, one week and three weeks following treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified IGA score</measure>
    <time_frame>at baseline, one week and three weeks following initiation of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypopigmentation scale score</measure>
    <time_frame>baseline, one and three weeks following initiation of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Pimecrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pimecrolimus 1% cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream over affected study area</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pimecrolimus active cream</intervention_name>
    <description>Pimecrolimus 1% cream apply to affected study area twice daily for 21 days</description>
    <arm_group_label>Pimecrolimus</arm_group_label>
    <other_name>Elidel 1% cream Novartis Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo base cream</intervention_name>
    <description>apply to affected study area twice daily for 21 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Elidel base cream without active agent</other_name>
    <other_name>by Novartis Pharmaceuticals</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African American children aged 2 to 17 years

          -  mild to moderate atopic dermatitis

        Exclusion Criteria:

          -  m-EASI less than 3 at baseline

          -  allergy to Elidel or components

          -  use of oral steroids, immunosuppressive agents,cytostatics of phototherapy within 4
             weeks prior to study.

          -  previous continuous or non-continuous use of pimecrolimus or tacrolimus for greater
             than 11 months within 2 weeks of enrollment.

          -  active skin infections.

          -  immunocompromised patients.

          -  previous history of skin cancer or lymphoma

          -  any hypopigmentation in study areas

          -  pregnant or breastfeeding

          -  participation in another investigational trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <last_update_submitted>December 17, 2008</last_update_submitted>
  <last_update_submitted_qc>December 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Paul J Munzenberger Pharm D Associate Professor</name_title>
    <organization>Children's Hospital of Michigan</organization>
  </responsible_party>
  <keyword>African American children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactitol</mesh_term>
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

